Merck & Co. Inc.'s stunning success in first-line metastatic lung cancer trials of Keytruda at the American Society of Clinical Oncology (ASCO) annual meeting set a high efficacy bar with prescribers and left its PD-1/L1 inhibitor rivals Bristol-Myers Squibb Co. and Roche on the defense.
Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO
With Merck's Keytruda on top of the world and setting the standard for PD-1/L1 lung cancer data, Roche and Bristol defended the programs for their competing Tecentriq and Opdivo during ASCO investor events.
More from Immuno-oncology
More from Anticancer
• By
The acquisition is worth up to $1bn and adds to AstraZeneca’s broad array of cell therapy technologies.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.
• By
A Phase III trial testing the protein degrader in breast cancer met the primary endpoint and showed an efficacy benefit only in the subgroup of ESR1 mutant patients, not the full population.